Supplemental material
Journal of Medical Economics
Volume 26, 2023 - Issue 1
Hematology
Impact of switching prophylaxis treatment from factor VIII to emicizumab in hemophilia A patients without inhibitors
Miguel Escobara Hematology, University of Texas Health Science Center, Houston, TX, USA
https://orcid.org/0000-0002-2944-0240
https://orcid.org/0000-0002-2944-0240, Neha Agrawalb Complete HEOR Solutions, North Wales, PA, USAhttps://orcid.org/0000-0002-1758-2786
https://orcid.org/0000-0002-1758-2786, Sagnik Chatterjeeb Complete HEOR Solutions, North Wales, PA, USAhttps://orcid.org/0000-0002-8800-7746
https://orcid.org/0000-0002-8800-7746, Swastik Bhattacharyab Complete HEOR Solutions, North Wales, PA, USAhttps://orcid.org/0000-0003-1585-0414
https://orcid.org/0000-0003-1585-0414, Jorge Caicedoc Takeda Pharmaceuticals U.S.A., Inc, Lexington, MA, USAhttps://orcid.org/0000-0002-5816-568X
https://orcid.org/0000-0002-5816-568X, Michael Bullanoc Takeda Pharmaceuticals U.S.A., Inc, Lexington, MA, USAhttps://orcid.org/0000-0002-9961-4576
https://orcid.org/0000-0002-9961-4576 & Bob G. Schultzc Takeda Pharmaceuticals U.S.A., Inc, Lexington, MA, USACorrespondence[email protected]
https://orcid.org/0000-0002-7023-8378
https://orcid.org/0000-0002-7023-8378 show all